7 research outputs found

    Tau immunohistochemistry from a <i>GRN</i>+/A152T+ patient diagnosed with unclassifiable tauopathy.

    No full text
    <p>(A) Strong diffuse neuronal cytoplasm immunoreactivity and threads in the cerebral cortex, x200. (B) Mild immunoreactivity in the neuronal cytoplasm and processes in the basal ganglia, x200. (C) Moderate diffuse neuronal cytoplasm immunoreactivity, some neurofibrillary tangles and grains in the neuronal processes in the amygdala, x200. (D) Moderate diffuse neuronal cytoplasm immunoreactivity in the neuronal cytoplasm of the dentate gyrus and threads in the hippocampus, x200.</p

    Tau immunohistochemistry from a <i>GRN</i>+/A152T+ patient.

    No full text
    <p>(A) Mild immunoreactivity in the neuronal cytoplasm and threads in the cerebral cortex, x200. (B) Isolated immunoreactivity in the neuronal cytoplasm and processes in the basal ganglia, x200. (C) Mild immunoreactivity in the cytoplasm and processes in the amygdala, x200. (D) Mild immunoreactivity in neuronal processes and lack of immunoreactivity in neuronal cytoplasm in the dentate gyrus of the hippocampus, x200.</p

    Additional file 1 of GOIZ ZAINDU study: a FINGER-like multidomain lifestyle intervention feasibility randomized trial to prevent dementia in Southern Europe

    No full text
    Additional file 1: Table 1S. Adherence degrees to each intervention component. Table 2S. Baseline cognitive performance per group. Table 3S. Post-intervention characteristics per groups. Table 4S. Effect of intervention in cognitive change between pre-intervention and post-intervention visits per group. Table 5S. Effect of intervention in cognitive change between pre-intervention and post-intervention visits per groups. Table 6S. Baseline demographic, CAIDE, and Cognition characteristics differences between good and bad adherence groups. Table 7S. Cognitive domain z scores at pre-intervention and post-intervention visits. Table 8S. Cognitive z scores at pre-intervention and post-intervention visits per group. Figure 1S. Number of participants in each adherence category
    corecore